Our Mission

Bring light to the blind epidural procedures using innovative technology to provide real-time visual guidance for training procedures with the aim to reduce the number of training procedures, reduce complications and increase successful procedures.

Our Story

Lumoptik, Inc is a medical device company that has developed the BrightPoint™ needle guidance system to assist physicians with needle placement during epidural procedures for childbirth, spine/back pain and surgical procedures such as knee and hip replacements.

Over 11 million epidural procedures are performed in the US each year. The large majority of these procedures are performed free hand by physicians with no mechanical or electronic needle guidance. Complications are common.

Management Team

Cole Hatfield

Chief Operations Officer

Board Member

Over 25 years of experience in product development and electronics manufacturing, having worked for innovative start-ups and Fortune 500 companies. He is passionate about developing long-term business strategies built on integrity, with a focus on creating lasting value for investors and driving sustainable growth. For the past six years, Cole has been a key leader at Lumoptik, contributing to its mission and success through strategic insight and operational excellence.

Andrew Alexander

DVM, Ph.D., MBA, DABT

Vice President

Results-oriented professional with over 30 years of experience in pharmaceutical, biotech, and medical device development, Andy brings a wealth of industry expertise and a proven track record of directing projects from concept to market extensive background in the development, testing, manufacturing, and commercialization of life science products. For the past seven years as Vice President at Lumoptik, he has been a driving force with designing and conducting nonclinical and clinical product testing.

Notable Milestones

Physician Focus Groups

Lumoptik conducted 3 physician focus groups with 21 anesthesiologists and nurse anesthetists before developing the Bright Point technology.

Hospital Teaching Programs

Lumoptik plans to introduce BrightPoint™ through hospital teaching programs. There are approximately 1,170 teaching hospitals in the US. This represents about 21% of the total hospitals in the US.

FDA Submission Testing

Bright Point has moved past the prototype stage and is now beginning to manufacture devices for FDA submission testing, conducted multiple animal studies proving the device works, filed a patent to protect the intellectual property (more are planned) and hired an experienced medical device CEO to guide the company.